| Name | Title | Contact Details |
|---|
Seattle based Littlebird believes that building better connections and providing greater communication will lead to better results for you, your caregiver, and child. Littlebird`s state-of-the-art wearable device connects parents with their child anywhere, anytime, with on-demand information about who they are with, where they are located, what they are doing, and how they are feeling. Littlebird`s innovative technology and secure digital platform offers parents unique insights into their child`s safety, health and overall well-being. Littlebird`s 24/7 GPS and cellular connectivity enables up-to-date notifications regarding your child`s location, which "approved" caregiver they are with and what they are doing. Littlebird also provides key metrics regarding your child`s heartrate, daily activity, sleep patterns and much more so you can better understand your child`s specific needs. The intuitively designed app also provides a private chat with photo capabilities connecting you and your caregiver(s) so you never miss a moment of your toddler`s day.
Brisar Delvco is a Paterson, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
American Sports Medicine Institute is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Prestige Medical Esthetics is a Medispa specializing in cosmetic procedures ranging from Botox to Injectables, Microneedling, and the latest Laser procedures.
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.